While MET alterations encompass a broad spectrum, MET protein overexpression is the most prevalent MET abnormality observed in advanced NSCLC and is easily assessed in clinical practice through immunohistochemistry (IHC). This evidence concerns the gene MET and non-small cell lung carcinoma.